Clinical trial Recruiting at 1 site Observational Ages 18 to 85

Comparing different access methods for treating acute deep vein thrombosis

Official title: Comparison Of Percutaneous Mechanical Thrombectomy With Different Access in Treatment of Acute Deep Venous Thrombosis (The CODA Study)

Run by RenJi Hospital · NCT06124768 · Data updated 2026-11-12

This study is testing two different ways to access veins for treating acute deep vein thrombosis to see if they can improve outcomes compared to the usual method.

Quick facts

Study typeObservational
Ages18 Years to 85 Years
SexAll
Enrollment210 (estimated)
SponsorRenJi Hospital
Academic / other
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedJanuary 1, 2021
Main results expectedOctober 31, 2026
Study endsOctober 31, 2027
Registry record updatedFebruary 25, 2026
Trial IDNCT06124768 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18-85 who have experienced acute DVT within the last 14 days and are eligible for percutaneous mechanical thrombectomy.

Probably not a fit

Patients who are allergic to heparin or contrast agents, pregnant or lactating women, and those with life-limiting conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study compares two approaches for percutaneous mechanical thrombectomy (PMT) in patients with acute deep vein thrombosis (DVT). One approach uses ipsilateral deep calf venous access while the other uses contralateral femoral venous access, both aiming to improve treatment outcomes compared to the traditional ipsilateral popliteal venous access. The goal is to determine if the modified approaches can achieve similar therapeutic effects as those seen in central type DVT. The study seeks to provide high-level evidence for the endovascular treatment of acute DVT and its potential to reduce post-thrombotic syndrome incidence.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment options for patients with acute deep vein thrombosis, potentially reducing the risk of post-thrombotic syndrome.

How similar studies have gone: While this approach is innovative, previous studies have indicated that addressing residual thrombus can enhance the efficacy of PMT, suggesting potential for success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age between 18-85 years old;
2. Acute DVT occurred no more than 14 days since the onset of disease;
3. DVT treated by percutaneous mechanical thrombectomy
4. Informed consent signed by patients.

Exclusion Criteria:

1. Patients who are known to be allergic to heparin, low molecular weight heparin, or contrast agent;
2. Women during pregnancy and lactation;
3. Patients with other diseases that may cause difficulty in the study or significantly shorten the life expectancy of patients (\<6 months);
4. Patients who are unable or unwilling to participate in the study.

Where it's running

  • Renji Hospital
    Shanghai, Shanghai Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.